In this video, Drs. Eric Donnenfeld and Vance Thompson discuss incorporating presbyopia therapies into practice for older patients. By the end of this video, you will learn the role of surgical and pharmaceutical management with older patients.
This activity is supported by unrestricted educational grants from AcuFocus, Johnson & Johnson Vision, and Visus.
Upon completion of this activity, the participant should be able to:
Jointly Provided by Evolve Medical Education and The Fundingsland Group.
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education LLC (Evolve) and The Fundingsland Group. Evolve is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
Evolve Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Eric D. Donnenfeld, MD
Ophthalmic Consultants of Long Island and Connecticut
Trustee, Dartmouth Medical School
Clinical Professor of Ophthalmology
New York University
New York, NY
Vance Thompson, MD, FACS
Founder, Vance Thompson Vision
Professor of Ophthalmology
University of South Dakota
Sanford School of Medicine
Sioux Falls, SD
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
Eric D. Donnenfeld, MD,has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant:Allegro, Allergan, Alcon, Avellino Labs, Bausch + Lomb, Carl Zeiss Meditec, CorneaGen, Covalent, CRST, BVI, Blephex, Dompé, ELT Sight, EyePoint Pharmaceuticals, Foresight, Glaukos, Ivantis, Johnson & Johnson Vision, Kala, Katena, Lacripen, LensGen, Mati Pharmaceuticals, MDBackline, Merck, Mimetogen, Nanowafer, Novabay, Novaliq, Novartis, Ocuhub, Ocular Innovations, Oculus, Odyssey, Omega Ophthalmics, Omeros, Oyster Point Therapeutics, Pfizer, Pogotec, PRN, RegenerEyes, ReTear, RPS, Shire, Strathspey Crown, Sun Pharmaceutical Industries, Surface, Tarsus, TearLab, Tearscience, Thea, TLC Laser Centers, Veracity, Versant Ventures, Visionary Venture, and Visus. Stock/Shareholder: Avedro, CorneaGen, Covalent, ELT Sight, EyePoint Pharmaceuticals, Glaukos, Ivantis, Lacripen, LensGen, Mati Pharmaceuticals, MDBackline, Mimetogen, Novabay, Ocuhub, Ocular Innovations, Oculus, Orasis, Pogotec, RegenerEyes, ReTear, RPS, Strathspey Crown, Surface, Tarsus, Tearlab, Veracity, Versant Ventures, Visionary Ventures, and Visus.
Vance Thompson, MD, FACS, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AcuFocus, Alcon, Allergan, Allotex, Avellino, Avisi Technologies, Bausch + Lomb, BRIM, BVI, Carl Zeiss Meditec, Centricity, Conjtac, CSO, D&D, Equinox, Euclid Systems, Expert Opinion, eyeBrain Medical, Eyedetec, EyeGate, Eyesafe, FemtoVision, Forsight Robotics, Glaukos, Imprimis, iVeena, Johnson & Johnson Vision, Leica, LensAR, Melt, Ocular Innovations, OneFocus, ORA, OysterPoint, Percept, ReFocus, RxSight, SightSciences, Stepwise Medical, Stuart Therapeutics, Tarsus, TeraClear, TearOptix, TherOptix, Treehouse Health, Veracity, Visant, Visus, and Vivior. Stock Shareholder: AcuFocus, AI Optics, Allotex, Avellino, Avisi, Conjtac, D&D, Equinox, Euclid, Expert Opinion, eyeBrain Medical, Eyedetec, EyeGate, Eyesafe, FemtoVision, Forsight Robotics, iVeena, Melt, Ocular Innovations, OneFocus, OysterPoint, Percept, RxSight, SightSciences, Singular Strategies, Stuart, Tarsus, TearClear, TearOptix, TherOptix, Treehouse Health, Veracity, Visant, Visus, and Vivior.
The Evolve and The Fundingsland Group staff and planners have no financial relationships with ineligible companies.
Nisha Mukherjee, MD, peer reviewer, has no financial relationships with ineligible companies.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, AcuFocus, Johnson & Johnson Vision, or Visus.
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Eric D. Donnenfeld, MD
Marjan Farid, MD
Jason J. Jones, MD
Eva I. Liang, MD, FACS
Carlton Yuen, MD
